Aptiv price target raised to $94 from $92 at Guggenheim

Guggenheim analyst Ronald Jewsikow raised the firm’s price target on Aptiv to $94 from $92 and keeps a Buy rating on the shares following the company’s Q1 report last week. The updated FY24 guidance better balances risks, now assuming lower revenue, with margins being “far more resilient than we expected,” the analyst tells investors.